360 related articles for article (PubMed ID: 8573611)
1. Transduction of rIL-2 expanded CD4+ and CD8+ ovarian TIL-derived T cell lines with the G1Na (neor) replication-deficient retroviral vector.
Nash MA; Platsoucas CD; Wong BY; Wong PM; Cottler-Fox M; Otto E; Freedman RS
Hum Gene Ther; 1995 Nov; 6(11):1379-89. PubMed ID: 8573611
[TBL] [Abstract][Full Text] [Related]
2. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
3. Retrovirus-mediated gene transfer into CD4+ and CD8+ human T cell subsets derived from tumor-infiltrating lymphocytes and peripheral blood mononuclear cells.
Morecki S; Karson E; Cornetta K; Kasid A; Aebersold P; Blaese RM; Anderson WF; Rosenberg SA
Cancer Immunol Immunother; 1991; 32(6):342-52. PubMed ID: 2007247
[TBL] [Abstract][Full Text] [Related]
4. Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells.
Kooi S; Freedman RS; Rodriguez-Villanueva J; Platsoucas CD
Lymphokine Cytokine Res; 1993 Dec; 12(6):429-37. PubMed ID: 8123759
[TBL] [Abstract][Full Text] [Related]
5. Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin.
Merrouche Y; Negrier S; Bain C; Combaret V; Mercatello A; Coronel B; Moskovtchenko JF; Tolstoshev P; Moen R; Philip T
J Clin Oncol; 1995 Feb; 13(2):410-8. PubMed ID: 7844602
[TBL] [Abstract][Full Text] [Related]
6. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy.
Freedman RS; Tomasovic B; Templin S; Atkinson EN; Kudelka A; Edwards CL; Platsoucas CD
J Immunol Methods; 1994 Jan; 167(1-2):145-60. PubMed ID: 8308273
[TBL] [Abstract][Full Text] [Related]
7. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
8. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.
Kooi S; Zhang HZ; Patenia R; Edwards CL; Platsoucas CD; Freedman RS
Cell Immunol; 1996 Dec; 174(2):116-28. PubMed ID: 8954611
[TBL] [Abstract][Full Text] [Related]
9. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
Ogasawara M; Rosenberg SA
Cancer Res; 1993 Aug; 53(15):3561-8. PubMed ID: 8101762
[TBL] [Abstract][Full Text] [Related]
10. Retroviral transduction of protein kinase C-gamma into tumor-specific T cells allows antigen-independent long-term growth in IL-2 with retention of functional specificity in vitro and ability to mediate tumor therapy in vivo.
Chen W; Schweins E; Chen X; Finn OJ; Cheever MA
J Immunol; 1994 Oct; 153(8):3630-8. PubMed ID: 7930583
[TBL] [Abstract][Full Text] [Related]
11. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL
Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139
[TBL] [Abstract][Full Text] [Related]
12. Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man.
Kasid A; Morecki S; Aebersold P; Cornetta K; Culver K; Freeman S; Director E; Lotze MT; Blaese RM; Anderson WF
Proc Natl Acad Sci U S A; 1990 Jan; 87(1):473-7. PubMed ID: 2404283
[TBL] [Abstract][Full Text] [Related]
13. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.
Economou JS; Belldegrun AS; Glaspy J; Toloza EM; Figlin R; Hobbs J; Meldon N; Kaboo R; Tso CL; Miller A; Lau R; McBride W; Moen RC
J Clin Invest; 1996 Jan; 97(2):515-21. PubMed ID: 8567975
[TBL] [Abstract][Full Text] [Related]
14. Applications of the polymerase chain reaction in retroviral-mediated gene transfer and the analysis of gene-marked human TIL cells.
Morgan RA; Cornetta K; Anderson WF
Hum Gene Ther; 1990; 1(2):135-49. PubMed ID: 1964093
[TBL] [Abstract][Full Text] [Related]
15. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion.
Dadmarz RD; Ordoubadi A; Mixon A; Thompson CO; Barracchini KC; Hijazi YM; Steller MA; Rosenberg SA; Schwartzentruber DJ
Cancer J Sci Am; 1996; 2(5):263-72. PubMed ID: 9166543
[TBL] [Abstract][Full Text] [Related]
17. Use of a retroviral vector to study the trafficking patterns of purified ovarian tumor infiltrating lymphocytes (TIL) used in intraperitoneal adoptive immunotherapy of ovarian cancer patients. A pilot study.
Freedman RS; Platsoucas CD; Deisseroth AB
Hum Gene Ther; 1996 Jul; 7(11):1351-65. PubMed ID: 8818723
[No Abstract] [Full Text] [Related]
18. Simultaneous use of two retroviral vectors in human gene marking trials: feasibility and potential applications.
Miller AR; Skotzko MJ; Rhoades K; Belldegrun AS; Tso CL; Kaboo R; McBride WH; Jacobs E; Kohn DB; Moen R
Hum Gene Ther; 1992 Dec; 3(6):619-24. PubMed ID: 1482701
[TBL] [Abstract][Full Text] [Related]
19. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
